Figure 1. Study design of primary efficacy endpoints




Figure 2a. Trial profile Cohort 1




Figure 2b. Trial profile cohort 2





Figure 3a. Kaplan-Meier curve for the proportion of children with at least one episode of clinical malaria



At risk								
	(C)	745	655	607	583	581	565	344
	(R)	745	692	651	635	626	588	418

Figure 3b. Kaplan-Meier curve for the proportion of children with at least one episode of malaria infection

